



# Female Urinary Incontinence Smart Set

IT<sup>2</sup> Team – Northwestern Medicine

**Resource Description:** This document contains the Smart Set—an EHR clinical decision-making tool—that the IT<sup>2</sup> team provided to clinicians.

---

This project was funded under grant number U18HS028744 from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services (HHS). The authors are solely responsible for this document's contents, findings, and conclusions, which do not necessarily represent the views of AHRQ or of HHS. Readers should not interpret any statement in this report as an official position of AHRQ or of HHS. None of the authors has any affiliation or financial involvement that conflicts with the material presented in this report.

---

## IT<sup>2</sup> Clinician Smart Set

### Referrals

- NM PHYSICAL THERAPY REFERRAL (PELVIC)
- UROGYNECOLOGY REFERRAL
- UROLOGY REFERRAL

### Medications

- Beta<sub>3</sub> Agonist Medications (Monitor blood pressure when mirabegron used)
- Mirabegron 25 mg oral TB24
- Mirabegron 50 mg oral TB24
- Vibegron 75 mg oral tab
- Antimuscarinic Medications (Assess for efficacy and adverse effects within the first three months of use)
- Darifenacin ER 7.5 mg oral TB24
- Oxybutinin IR 5 mg oral tab
- Oxybutinin ER 5 mg oral TB24
- Oxybutinin ER 10 mg oral TB24
- Oxybutinin ER 15 mg oral TB24
- Trospium ER 60 mg oral TB24
- Trospium IR 20 mg oral tab

### Patient instructions

- Wisercare Link
- Behavioral modifications for over active bladder
- What is Stress Incontinence
- What is Pelvic Floor PT
- Antimuscarinic medications
- Beta 3 agonists

### Diagnoses

- Stress incontinence
- Urge incontinence
- Mixed urge and stress incontinence